Acorda Therapeutics Inc (ACORQ)
0.605
+0.10
(+18.63%)
USD |
OTCM |
May 17, 16:00
Acorda Therapeutics Revenue (Quarterly): 20.29M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.29M |
| December 31, 2023 | 37.98M |
| September 30, 2023 | 27.72M |
| June 30, 2023 | 29.68M |
| March 31, 2023 | 22.26M |
| December 31, 2022 | 31.47M |
| September 30, 2022 | 33.51M |
| June 30, 2022 | 31.05M |
| March 31, 2022 | 22.53M |
| December 31, 2021 | 36.97M |
| September 30, 2021 | 31.46M |
| June 30, 2021 | 31.78M |
| March 31, 2021 | 28.86M |
| December 31, 2020 | 38.16M |
| September 30, 2020 | 53.09M |
| June 30, 2020 | 33.62M |
| March 31, 2020 | 28.10M |
| December 31, 2019 | 50.50M |
| September 30, 2019 | 47.72M |
| June 30, 2019 | 50.05M |
| March 31, 2019 | 44.14M |
| December 31, 2018 | 69.15M |
| September 30, 2018 | 142.81M |
| June 30, 2018 | 153.30M |
| March 31, 2018 | 106.16M |
| Date | Value |
|---|---|
| December 31, 2017 | 188.40M |
| September 30, 2017 | 141.06M |
| June 30, 2017 | 139.44M |
| March 31, 2017 | 119.39M |
| December 31, 2016 | 140.63M |
| September 30, 2016 | 135.61M |
| June 30, 2016 | 127.46M |
| March 31, 2016 | 115.90M |
| December 31, 2015 | 130.90M |
| September 30, 2015 | 148.20M |
| June 30, 2015 | 113.71M |
| March 31, 2015 | 99.85M |
| December 31, 2014 | 117.87M |
| September 30, 2014 | 105.96M |
| June 30, 2014 | 97.13M |
| March 31, 2014 | 80.52M |
| December 31, 2013 | 92.59M |
| September 30, 2013 | 84.92M |
| June 30, 2013 | 87.05M |
| March 31, 2013 | 71.86M |
| December 31, 2012 | 81.47M |
| September 30, 2012 | 77.44M |
| June 30, 2012 | 75.66M |
| March 31, 2012 | 71.25M |
| December 31, 2011 | 72.64M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
20.29M
Minimum
Mar 2024
53.09M
Maximum
Sep 2020
34.34M
Average
31.63M
Median
Revenue (Quarterly) Benchmarks
| BioSig Technologies Inc | 0.012M |
| Verve Therapeutics Inc | 5.695M |
| Spectral AI Inc | 3.44M |
| AIM ImmunoTech Inc | 0.065M |
| Protalix BioTherapeutics Inc | 3.748M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -27.40M |
| Total Expenses (Quarterly) | 33.68M |
| EPS Diluted (Quarterly) | -22.06 |
| Enterprise Value | 182.86M |
| Gross Profit Margin (Quarterly) | 81.73% |
| Profit Margin (Quarterly) | -135.0% |
| Earnings Yield | -35.06K% |
| Normalized Earnings Yield | -6821.73 |